ECSP22016567A - Compuestos inhibidores de rip1 y m?todos para prepararlos y usarlos - Google Patents
Compuestos inhibidores de rip1 y m?todos para prepararlos y usarlosInfo
- Publication number
- ECSP22016567A ECSP22016567A ECSENADI202216567A ECDI202216567A ECSP22016567A EC SP22016567 A ECSP22016567 A EC SP22016567A EC SENADI202216567 A ECSENADI202216567 A EC SENADI202216567A EC DI202216567 A ECDI202216567 A EC DI202216567A EC SP22016567 A ECSP22016567 A EC SP22016567A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitor compounds
- rip1
- preparing
- methods
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 102100021009 Cytochrome b-c1 complex subunit Rieske, mitochondrial Human genes 0.000 title 1
- 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 title 1
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 title 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 5
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 5
- 229940043355 kinase inhibitor Drugs 0.000 abstract 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente descripci?n se describen compuestos inhibidores de quinasa, tales como compuestos inhibidores de quinasa de prote?na 1 que interact?a con el receptor (RIP1), as? como tambi?n composiciones farmac?uticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos, composiciones farmac?uticas y/o combinaciones descritos pueden usarse para tratar o prevenir una enfermedad o afecci?n asociada a la quinasa, particularmente una enfermedad o afecci?n asociada a RIP1.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962897223P | 2019-09-06 | 2019-09-06 | |
| US201962932404P | 2019-11-07 | 2019-11-07 | |
| US202063001016P | 2020-03-27 | 2020-03-27 | |
| US202063004290P | 2020-04-02 | 2020-04-02 | |
| US202063004319P | 2020-04-02 | 2020-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22016567A true ECSP22016567A (es) | 2022-08-31 |
Family
ID=72613994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202216567A ECSP22016567A (es) | 2019-09-06 | 2022-03-04 | Compuestos inhibidores de rip1 y m?todos para prepararlos y usarlos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11564930B2 (es) |
| EP (1) | EP4025575B1 (es) |
| JP (2) | JP7493586B2 (es) |
| KR (1) | KR102793185B1 (es) |
| CN (1) | CN114728958B (es) |
| AU (1) | AU2020341708B2 (es) |
| BR (1) | BR112022002378A2 (es) |
| CA (1) | CA3149729A1 (es) |
| CO (1) | CO2022002374A2 (es) |
| CR (1) | CR20220075A (es) |
| DO (1) | DOP2022000042A (es) |
| EC (1) | ECSP22016567A (es) |
| IL (1) | IL290781A (es) |
| JO (1) | JOP20220056A1 (es) |
| MX (1) | MX2022002717A (es) |
| MY (1) | MY198690A (es) |
| PE (1) | PE20221762A1 (es) |
| PH (1) | PH12022550537A1 (es) |
| PY (2) | PY2052230A (es) |
| TW (1) | TW202122397A (es) |
| WO (1) | WO2021046437A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3788045T2 (ro) | 2018-05-03 | 2023-09-30 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| JP7493586B2 (ja) | 2019-09-06 | 2024-05-31 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法 |
| SI4055021T1 (sl) * | 2019-11-07 | 2026-02-27 | Rigel Pharmaceuticals, Inc. | Heterociklične spojine, ki inhibirajo rip1 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI840311B (zh) | 2020-07-01 | 2024-04-21 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| AR125587A1 (es) | 2021-03-11 | 2023-08-02 | Rigel Pharmaceuticals Inc | Inhibidores heterocíclicos de la quinasa de rip1 |
| WO2022237890A1 (zh) * | 2021-05-14 | 2022-11-17 | 中国医药研究开发中心有限公司 | 氮杂卓类稠环化合物及其医药用途 |
| WO2022258052A1 (zh) * | 2021-06-11 | 2022-12-15 | 劲方医药科技(上海)有限公司 | 杂环内酰胺类化合物，其制法与医药上的用途 |
| WO2023138317A1 (zh) * | 2022-01-21 | 2023-07-27 | 中国科学院上海药物研究所 | 具有ripk1抑制活性的化合物、其制备方法及其用途 |
| TW202400588A (zh) * | 2022-02-28 | 2024-01-01 | 香港商維泰瑞隆（香港）生物科技有限公司 | Ｒｉｐ１調製劑、其製備及用途 |
| CN115201250B (zh) * | 2022-09-14 | 2022-11-25 | 中铁三局集团第三工程有限公司 | 一种冷再生沥青混合料热可逆老化程度的量化方法 |
| CN121969374A (zh) | 2023-06-26 | 2026-05-01 | 伊莱利利公司 | 使用ly3871801治疗自身免疫性和炎症性疾病的剂量方案 |
| WO2025153090A1 (zh) * | 2024-01-19 | 2025-07-24 | 无锡奕拓医药科技有限责任公司 | 一种多并环化合物、其药物组合物及其用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| DK0431519T3 (da) | 1989-12-04 | 1994-07-04 | Searle & Co | System til transdermal indgivelse af albuterol |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| DE69228827T2 (de) | 1991-12-18 | 1999-10-21 | Minnesota Mining And Mfg. Co., Saint Paul | Mehrschichtige sperrstrukturen |
| ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| EP2192838A4 (en) | 2007-08-15 | 2011-07-27 | Harvard College | HETEROCYCLIC NEKROPTOSIS HEMMER |
| TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| CN106573006A (zh) | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
| BR112017017411A2 (pt) | 2015-02-13 | 2018-04-03 | Glaxosmithkline Ip Dev Ltd | Formas cristalinas de (s)-5-benzil-n-(5-metil-4-oxo- 2,3,4,5-tetraidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamida |
| EP3317269B1 (en) | 2015-07-02 | 2022-09-21 | F. Hoffmann-La Roche AG | Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases |
| ES2885474T3 (es) | 2015-10-13 | 2021-12-13 | Inst Nat Sante Rech Med | Derivados de sibirilina para la utilización en la prevención y/o tratamiento de trastornos asociados a la necroptosis celular |
| AU2016340527B2 (en) * | 2015-10-23 | 2020-09-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| IL287136B2 (en) | 2016-02-05 | 2023-09-01 | Denali Therapeutics Inc | Receptor inhibitors - interacting with protein kinase 1 |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| US20200062735A1 (en) | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CN111655678B (zh) | 2018-01-05 | 2023-08-22 | 广州市恒诺康医药科技有限公司 | 细胞凋亡信号调节激酶-1抑制剂及其应用 |
| HRP20231381T1 (hr) | 2018-05-03 | 2024-03-01 | Rigel Pharmaceuticals, Inc. | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu |
| MD3788045T2 (ro) | 2018-05-03 | 2023-09-30 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
| TW202019913A (zh) | 2018-06-26 | 2020-06-01 | 中國科學院上海有機化學研究所 | 細胞壞死抑制劑及其製備方法和用途 |
| WO2020088194A1 (zh) | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| JP7493586B2 (ja) | 2019-09-06 | 2024-05-31 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法 |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2020
- 2020-09-04 JP JP2022514840A patent/JP7493586B2/ja active Active
- 2020-09-04 EP EP20775994.5A patent/EP4025575B1/en active Active
- 2020-09-04 CR CR20220075A patent/CR20220075A/es unknown
- 2020-09-04 PE PE2022000317A patent/PE20221762A1/es unknown
- 2020-09-04 CA CA3149729A patent/CA3149729A1/en active Pending
- 2020-09-04 PH PH1/2022/550537A patent/PH12022550537A1/en unknown
- 2020-09-04 BR BR112022002378A patent/BR112022002378A2/pt unknown
- 2020-09-04 TW TW109130524A patent/TW202122397A/zh unknown
- 2020-09-04 KR KR1020227007063A patent/KR102793185B1/ko active Active
- 2020-09-04 US US17/013,284 patent/US11564930B2/en active Active
- 2020-09-04 WO PCT/US2020/049527 patent/WO2021046437A1/en not_active Ceased
- 2020-09-04 MY MYPI2022001240A patent/MY198690A/en unknown
- 2020-09-04 AU AU2020341708A patent/AU2020341708B2/en active Active
- 2020-09-04 CN CN202080062742.0A patent/CN114728958B/zh active Active
- 2020-09-04 MX MX2022002717A patent/MX2022002717A/es unknown
- 2020-09-07 PY PY202002052230A patent/PY2052230A/es unknown
- 2020-09-07 PY PY202002052258A patent/PY2052258A/es unknown
-
2022
- 2022-02-21 IL IL290781A patent/IL290781A/en unknown
- 2022-02-22 DO DO2022000042A patent/DOP2022000042A/es unknown
- 2022-02-28 CO CONC2022/0002374A patent/CO2022002374A2/es unknown
- 2022-03-02 JO JOP/2022/0056A patent/JOP20220056A1/ar unknown
- 2022-03-04 EC ECSENADI202216567A patent/ECSP22016567A/es unknown
-
2024
- 2024-01-04 JP JP2024000045A patent/JP2024050568A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020341708B2 (en) | 2024-01-04 |
| JP7493586B2 (ja) | 2024-05-31 |
| CO2022002374A2 (es) | 2022-08-09 |
| PY2052230A (es) | 2021-10-05 |
| US20210069208A1 (en) | 2021-03-11 |
| EP4025575B1 (en) | 2025-12-17 |
| DOP2022000042A (es) | 2022-08-15 |
| AU2020341708A1 (en) | 2022-03-17 |
| CA3149729A1 (en) | 2021-03-11 |
| IL290781A (en) | 2022-04-01 |
| CR20220075A (es) | 2022-07-14 |
| BR112022002378A2 (pt) | 2022-06-14 |
| US11564930B2 (en) | 2023-01-31 |
| JP2024050568A (ja) | 2024-04-10 |
| JP2022546605A (ja) | 2022-11-04 |
| MY198690A (en) | 2023-09-16 |
| PY2052258A (es) | 2022-05-10 |
| PH12022550537A1 (en) | 2023-03-20 |
| TW202122397A (zh) | 2021-06-16 |
| EP4025575A1 (en) | 2022-07-13 |
| WO2021046437A1 (en) | 2021-03-11 |
| MX2022002717A (es) | 2022-08-10 |
| KR102793185B1 (ko) | 2025-04-09 |
| PE20221762A1 (es) | 2022-11-11 |
| CN114728958A (zh) | 2022-07-08 |
| CN114728958B (zh) | 2025-05-02 |
| JOP20220056A1 (ar) | 2023-01-30 |
| KR20220042206A (ko) | 2022-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22016571A (es) | Compuestos inhibidores de rip1 y m?todos para hacer y utilizar los mismos | |
| ECSP22016567A (es) | Compuestos inhibidores de rip1 y m?todos para prepararlos y usarlos | |
| DOP2023000169A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| ECSP22076856A (es) | Inhibidores de rip1k | |
| ECSP20077518A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| MX2022005509A (es) | Compuestos inhibidores de rip1 heterociclicos. | |
| CO2023000051A2 (es) | Inhibidores de rip1k | |
| PY2055444A (es) | Composiciones nematicidas | |
| AR120412A1 (es) | Compuestos heterocíclicos inhibidores de rip1 | |
| CO2023012077A2 (es) | Inhibidores heterocíclicos de la cinasa rip1 |